How Semaglutide Affects hs-CRP

Semaglutide reduces the upstream drivers of hepatic CRP synthesis rather than acting on CRP itself. CRP is produced in the liver in response to IL-6, so anything that suppresses IL-6 production tends to pull CRP down with it.

1. IL-6 and TNF-alpha suppression: GLP-1 receptor activation on hepatocytes, adipocytes and macrophages attenuates NF-kB signalling and reduces production of the cytokines that drive hepatic CRP synthesis. Adipose tissue macrophage infiltration falls, and the classically-activated M1 phenotype shifts toward the anti-inflammatory M2 phenotype.
2. Adipose tissue anti-inflammatory effect: Visceral fat is a major source of chronic low-grade inflammation. Semaglutide's weight loss preferentially strips visceral fat, which reduces adipokine-driven inflammation as a separate mechanism from direct GLP-1R signalling.
3. Weight-independent component: The SELECT prespecified analysis (Plutzky et al., 2026, PMID 42610271) showed hs-CRP reduction was significant even in participants who did not achieve weight loss. This confirms the drug does more than just cut adipose inflammation.
4. Insulin sensitivity: Improved insulin signalling reduces hyperinsulinemia-driven inflammatory tone, contributing to the total effect.

The Berkeley mouse lifespan paper (Feng et al., 2026, Nature) reported large drops in SASP inflammatory cytokines and cellular senescence markers, and hs-CRP is the closest available human proxy for the mouse SASP finding.

Standard doses (1.0-2.4 mg per week):

• hs-CRP falls by approximately 38% versus placebo at 104 weeks (SELECT trial, Plutzky et al., 2026)
• Effect is visible by weeks 4 to 8: approximately 12% at week 4, approximately 20% at week 8
• STEP 1, 2 and 3 pooled analyses showed treatment differences of 39% to 48% at week 68 (Verma et al., 2023)
• A baseline hs-CRP of 2 mg/L typically falls to approximately 1.2 mg/L on treatment

Microdose (0.25 mg per week):

• No controlled human evidence that microdose delivers the same anti-inflammatory effect
• The mouse dose in Feng et al. (2026) allometrically scales to approximately 1.6 mg per week, not 0.25 mg
• Anti-inflammatory extrapolation from microdose is off-label and unproven

Discontinuation:

• hs-CRP rebounds toward baseline within weeks of stopping unless the weight loss holds
• The kidney-slope and cardiovascular benefits from FLOW and SELECT are only bought while dosing

Baseline: hs-CRP before starting, drawn at least 5 days clear of anything heavy or novel in training, and at the same lab and time of day for reliability. Rule out active infection, recent injury, or a hard training session in the previous 48 hours before crediting an elevation to anything else.

Interpret against variation, not the number: within-subject coefficient of variation for hs-CRP is roughly 41%. A drop from 3 mg/L to 2 mg/L sits inside biological noise. A sustained 40% or more reduction, confirmed on a repeat draw, is a signal.

Timing on treatment: recheck at week 4 (early response), week 12 (approaching steady state), and week 24 (confirmed effect). If using semaglutide for a longevity motive rather than weight loss, hs-CRP is the primary readout to track.

If hs-CRP stays above 3 mg/L on treatment: rule out training-induced elevation, infection, and body-composition drift before assuming the drug is not working. Consider adding faecal calprotectin if gut inflammation is suspected, since a systemic marker cannot localise the source.

If hs-CRP stays above 10 mg/L: stop attributing to any single cause and investigate properly.

Fix the drivers before crediting the drug: NSAID use, hard training in heat, chronically low fibre intake and unresolved sleep deprivation all elevate hs-CRP measurably. A drug layered on top of unchanged inflammatory drivers produces uninterpretable results.

Change one variable at a time: starting semaglutide, a new training block and a diet change in the same week gives you an experiment with no control.

Dose matters for the longevity claim: the current human evidence for meaningful anti-inflammatory effect is at 1.0 to 2.4 mg per week. Cruise microdosing (0.25 mg per week) is theoretical extrapolation and has not been tested for hs-CRP endpoints.

Combine with muscle-preserving practices: semaglutide monotherapy strips roughly 30-40% of weight loss from lean mass. Adequate protein (2+ g/kg per day) and resistance training preserve muscle and independently reduce hs-CRP.

Further reading: How semaglutide extended lifespan 12% in old female mice. GLP-1 bloodwork: what to test on semaglutide and tirzepatide.